AI Engines For more Details: Perplexity Kagi Labs You
Eye Inflammation: Rimexolone is indicated for the treatment of inflammation of the eye structures, including the conjunctiva, cornea, and anterior segment of the eye. It is commonly used to manage conditions such as anterior uveitis, iritis, and keratitis.
Allergic Conjunctivitis: Rimexolone may be prescribed for the treatment of allergic conjunctivitis, an allergic reaction affecting the conjunctiva (the thin, transparent membrane covering the white part of the eye).
Postoperative Inflammation: Following ocular surgery, rimexolone can help reduce inflammation and promote healing. It is often used after procedures such as cataract surgery or refractive surgery to minimize postoperative inflammation and discomfort.
Steroid-Responsive Conditions: Rimexolone is effective in managing steroid-responsive ocular conditions, where inflammation plays a significant role in disease pathogenesis and symptomatology.
Side Effects: While rimexolone is generally well-tolerated when used appropriately in ophthalmic applications, it can still cause side effects, especially with prolonged or high-dose use. Common side effects may include temporary burning or stinging upon instillation, blurred vision, increased intraocular pressure (IOP), and delayed wound healing.
Increased Intraocular Pressure (IOP): Prolonged use of rimexolone or other corticosteroids in the eye can lead to elevated intraocular pressure, which may increase the risk of glaucoma or worsen existing glaucoma in susceptible individuals. Therefore, patients using rimexolone should be monitored regularly for changes in intraocular pressure.
Cataract Formation: Long-term use of corticosteroids like rimexolone in the eye may contribute to the development or exacerbation of cataracts, particularly in predisposed individuals.
Infection Risk: Corticosteroids, including rimexolone, can mask the signs of ocular infections or exacerbate existing infections. Patients should be cautioned about the potential risk of secondary infections and advised to seek medical attention if they experience worsening symptoms or new ocular complaints while using rimexolone.
Hypersensitivity Reactions: Some individuals may experience hypersensitivity or allergic reactions to rimexolone or its components. Patients should discontinue use and seek medical advice if they develop signs of allergic reaction, such as itching, redness, swelling, or rash.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
| Acne | 0.1 | -0.1 | |
| ADHD | 1.7 | 0.6 | 1.83 |
| Age-Related Macular Degeneration and Glaucoma | 0.1 | 0.1 | 0 |
| Allergic Rhinitis (Hay Fever) | 0.5 | 0.2 | 1.5 |
| Allergies | 0.5 | 0.6 | -0.2 |
| Allergy to milk products | 0.5 | 0.2 | 1.5 |
| Alopecia (Hair Loss) | 0.2 | 0.2 | |
| Alzheimer's disease | 1.8 | 2 | -0.11 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1 | 0.4 | 1.5 |
| Ankylosing spondylitis | 0.5 | 0.8 | -0.6 |
| Anorexia Nervosa | 0.1 | 0.7 | -6 |
| Antiphospholipid syndrome (APS) | 0.2 | 0.1 | 1 |
| Asthma | 0.6 | 0.6 | 0 |
| Atherosclerosis | 0.5 | 0.4 | 0.25 |
| Atrial fibrillation | 1.2 | 0.6 | 1 |
| Autism | 2.8 | 2.6 | 0.08 |
| Barrett esophagus cancer | 0.3 | 0.1 | 2 |
| benign prostatic hyperplasia | 0.1 | 0.1 | |
| Bipolar Disorder | 0.6 | 0.9 | -0.5 |
| Brain Trauma | 0.1 | 0.3 | -2 |
| Carcinoma | 1.2 | 0.7 | 0.71 |
| Celiac Disease | 0.9 | 0.8 | 0.13 |
| Cerebral Palsy | 0.2 | 0.5 | -1.5 |
| Chronic Fatigue Syndrome | 2.1 | 2.5 | -0.19 |
| Chronic Kidney Disease | 0.7 | 0.8 | -0.14 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.8 | 0.5 | 0.6 |
| Chronic Urticaria (Hives) | 0.3 | 0.4 | -0.33 |
| Coagulation / Micro clot triggering bacteria | 0.4 | 0.4 | 0 |
| Colorectal Cancer | 2.2 | 0.2 | 10 |
| Constipation | 0.7 | 0.1 | 6 |
| Coronary artery disease | 0.4 | 0.4 | 0 |
| COVID-19 | 3 | 4.7 | -0.57 |
| Crohn's Disease | 3.3 | 2 | 0.65 |
| cystic fibrosis | 0.2 | 0.4 | -1 |
| deep vein thrombosis | 0.2 | 0.4 | -1 |
| Depression | 4.4 | 2.9 | 0.52 |
| Dermatomyositis | 0.1 | 0.1 | 0 |
| Eczema | 0.1 | 0.5 | -4 |
| Endometriosis | 1 | 0.3 | 2.33 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | |
| Epilepsy | 1 | 0.8 | 0.25 |
| Fibromyalgia | 0.4 | 1.5 | -2.75 |
| Functional constipation / chronic idiopathic constipation | 1.4 | 2 | -0.43 |
| gallstone disease (gsd) | 0.3 | 0.5 | -0.67 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.9 | 0.1 | 8 |
| Generalized anxiety disorder | 0.5 | 0.7 | -0.4 |
| Glioblastoma | 0.1 | -0.1 | |
| Gout | 0.4 | -0.4 | |
| Graves' disease | 0.4 | 0.1 | 3 |
| Halitosis | 0.5 | 0.1 | 4 |
| Hashimoto's thyroiditis | 0.5 | 0.4 | 0.25 |
| Hidradenitis Suppurativa | 0.5 | 0.5 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.9 | 0.2 | 3.5 |
| hypercholesterolemia (High Cholesterol) | 0.1 | 0.1 | 0 |
| hyperglycemia | 0.1 | 0.6 | -5 |
| Hyperlipidemia (High Blood Fats) | 0.1 | 0.1 | |
| hypersomnia | 0.1 | -0.1 | |
| hypertension (High Blood Pressure | 0.8 | 1.6 | -1 |
| Hypothyroidism | 0.7 | -0.7 | |
| Hypoxia | 0.4 | 0.4 | |
| IgA nephropathy (IgAN) | 0.7 | -0.7 | |
| Inflammatory Bowel Disease | 1.2 | 2.3 | -0.92 |
| Insomnia | 0.3 | 0.3 | 0 |
| Intelligence | 0.8 | 0 | 0 |
| Intracranial aneurysms | 0.5 | 0.5 | |
| Irritable Bowel Syndrome | 1.8 | 1.6 | 0.13 |
| Liver Cirrhosis | 1.8 | 1.2 | 0.5 |
| Long COVID | 3.6 | 2.2 | 0.64 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 1 | 0.3 | 2.33 |
| ME/CFS with IBS | 0.1 | 1.1 | -10 |
| ME/CFS without IBS | 1.1 | 0.5 | 1.2 |
| Menopause | 0.3 | 0.3 | |
| Metabolic Syndrome | 3.4 | 3.2 | 0.06 |
| Mood Disorders | 5.2 | 3.1 | 0.68 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.3 | |
| Multiple Sclerosis | 2.2 | 1.4 | 0.57 |
| Multiple system atrophy (MSA) | 0.7 | 0.2 | 2.5 |
| Neuropathy (all types) | 0.2 | 0.1 | 1 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.2 | 0.2 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.2 | 1.5 | -6.5 |
| NonCeliac Gluten Sensitivity | 0.1 | -0.1 | |
| Obesity | 2.8 | 1.7 | 0.65 |
| obsessive-compulsive disorder | 2 | 1.2 | 0.67 |
| Osteoarthritis | 0.5 | 0.2 | 1.5 |
| Osteoporosis | 0.7 | 0.4 | 0.75 |
| pancreatic cancer | 0.2 | 0.2 | |
| Parkinson's Disease | 1.3 | 1.5 | -0.15 |
| Polycystic ovary syndrome | 0.9 | 0.7 | 0.29 |
| Postural orthostatic tachycardia syndrome | 0.4 | -0.4 | |
| Premenstrual dysphoric disorder | 0.1 | 0.1 | 0 |
| primary biliary cholangitis | 0.4 | -0.4 | |
| Psoriasis | 0.7 | 1.2 | -0.71 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.4 | 1.4 | 0.71 |
| Rosacea | 0.2 | 0.1 | 1 |
| Schizophrenia | 2.1 | 0.7 | 2 |
| scoliosis | 0.4 | 0.3 | 0.33 |
| Sjögren syndrome | 0.4 | 1.1 | -1.75 |
| Sleep Apnea | 0.9 | 1 | -0.11 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.5 | 0.5 | |
| Stress / posttraumatic stress disorder | 1 | 1.4 | -0.4 |
| Systemic Lupus Erythematosus | 1.9 | 0.4 | 3.75 |
| Tic Disorder | 0.7 | 0.1 | 6 |
| Tourette syndrome | 0.1 | 0.2 | -1 |
| Type 1 Diabetes | 1.6 | 0.7 | 1.29 |
| Type 2 Diabetes | 3.8 | 2.8 | 0.36 |
| Ulcerative colitis | 0.6 | 2.3 | -2.83 |
| Unhealthy Ageing | 2.6 | 1 | 1.6 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.